1	
2	
3	
4	
5	
6	
7	
8	
9	Is artificial intelligence for medical professionals serving the
10	patients?
11	
12	Protocol for a mixed method systematic review on patient-relevant benefits
13	and harms of algorithmic decision-making.
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	Christoph Wilhelm <sup>4</sup> <sup>2</sup> , christoph.wilhelm@fgw-brandenburg.de, 1 <sup>st</sup> author (corresponding)
24 25	Prof. Dr. Anke Steckelberg <sup>2</sup> , anke.steckelberg@medizin.uni-halle.de, co-author
25 26	Dr. Felix G. Rebitschek <sup>-/-</sup> , rebitschek@uni-potsdam.de, co-author
20 27	<sup>1</sup> Harding Center for Risk Literacy, Faculty of Health Sciences Brandenburg, University of Potsdam
28	Virchowstr. 2. 14482 Potsdam. Germany
29	<sup>2</sup> Institute of Health and Nursing Science, Martin Luther University Halle-Wittenberg, Magdeburger
30	Str. 8, 06112 Halle (Saale), Germany
31	<sup>3</sup> Max Planck Institute for Human Development, Lentzeallee 94, 14195 Berlin, Germany
32	
33	Contributions
34 35	Christoph Wilhelm conceptualised, developed the methodology and wrote this protocol. He is the guarantor of the Manuscript.
36	Prof. Dr. Anke Steckelberg validated the methodology of this protocol.
37	Drofe in Graebits predicted and a new entries of the peared is pervised this protocolude clinical practice.

#### 38

# Abstract

# 39

#### 40 Background

41 Algorithmic decision making (ADM) utilizes algorithms to collect and process data and develop models 42 to make or support decisions. Advances in artificial intelligence (AI) have led to the development of 43 support systems that can be superior to medical professionals without AI support in certain tasks. 44 However, whether patients can benefit from this remains unclear. The aim of this systematic review is 45 to assess the current evidence on patient-relevant benefits and harms when healthcare professionals 46 use ADM systems (developed using or working with AI) compared to healthcare professionals without 47 Al-related ADM (standard care) - regardless of the clinical issues. Furthermore, for interpreting collected evidence and analysing preconditions for the implementation of AI-related ADM in 48 49 healthcare, experts from research, practice, and regulation will be interviewed.

#### 50 Methods

51 Following the PRISMA statement and the MECIR standards for reporting systematic reviews, MEDLINE 52 and PubMed (via PubMed), EMBASE (via Elsevier), IEEE Xplore, CENTRAL will be searched using English 53 free text terms in title/abstract, Medical Subject Headings (MeSH) terms and Embase Subject Headings 54 (Emtree) fields. Additional studies will be identified by contacting authors of included studies and through reference lists of included studies. Grey literature searches will be conducted in Google 55 56 Scholar. Risk of bias will be assessed by using Cochrane's RoB 2 for randomised trials and ROBINS-I for 57 non-randomised trials. Transparent reporting of the included studies will be assessed using the 58 CONSORT-AI extension statement. Following the SRQR statement, semi-structured interviews will be 59 conducted and analysed with the help of a qualitative content analysis according to Mayring. Based on 60 the research questions and the findings of the systematic review, the study and interview guide will be 61 developed a priori.

#### 62 Discussion

63 It is expected that there will be a substantial shortage of suitable studies that compare healthcare 64 professionals with and without ADM systems concerning patient-relevant endpoints. This can be 65 attributed to the prioritization of technical quality criteria and, in some cases, clinical parameters over 66 patient-relevant endpoints in the development of study designs. Furthermore, it is anticipated that a 67 significant portion of the identified studies will exhibit relatively poor methodological quality and provide only limited generalizable results. 68

69

70

71

#### 72 Systematic review registration

- This study is registered within Prospero (CRD42023412156). 73
- 74 Keywords: Algorithmic decision making, ADM, artificial intelligence, patient relevant, healthcare
- 75 professionals, decision support

# 76 Background

77 Artificial Intelligence (AI) is a broad term referring to the field of computer science that develops 78 algorithms mimicking human cognitive functions such as learning, perception, problem-solving, and 79 decision-making (McCarthy et al. 2006: 5-7). Al encompasses various approaches, including rule-based 80 systems, machine learning (ML), deep learning, and many others. It comprises a range of technologies 81 and techniques, including algorithmic decision-making (ADM) (Graili et al. 2021: 1). ADM refers to the 82 process of using algorithms to gather, process and model input data to inform or make automated 83 decisions. Feedback from these decisions can then be used by the system to improve itself (Araujo et 84 al. 2020: 612). An ADM can take various forms depending on how it is framed and presented to the 85 user or decision subject. It can be a simple algorithm that has been known and used for decades, such 86 as classification trees (von Winterfeldt & Edwards 1986), or a more complex system like a 87 recommender or AI that can provide recommendations to human decision-makers, nudge its users in 88 a certain direction, or perform fully automated decision-making processes without human involvement (Araujo et al. 2020: 613). To sum up, artificial intelligent related algorithmic decision-89 making systems (AI-related ADM) are decision support systems that either apply AI (e.g., relying on ML 90 91 models) or have been developed with the help of AI.

92 Recent advances in AI have resulted in the development of more complex and sophisticated systems 93 that can outperform humans in certain tasks. One such example is AlphaZero, a deep learning 94 algorithm developed by DeepMind, which uses reinforcement learning to learn how to play games like 95 chess, shogi, and Go without being explicitly programmed. In fact, AlphaZero has convincingly beaten 96 both human world champions and world champion computer applications in these games, simply by 97 inputting the rules of the game (Silver et al. 2018: 3-4). Another notable AI system is ChatGPT, 98 developed by OpenAI, which is a prototype text-based dialogue system that can generate human-like 99 text and imitate writing essays and business plans (Hughes 2023). It can also analyse and write code in 100 various programming languages, making it a valuable tool for debugging and code improvement 101 (OpenAI 2023). Recently, ChatGPT was evaluated for its clinical reasoning ability by testing its 102 performance on questions from the United States Medical Licensing Examination, where it scored at 103 or near the passing threshold on all three exams without any special training or reinforcement (Kung 104 et al. 2023).

105 These advances in AI seem to have enormous potential to transform many different fields and 106 industries, which begs the question: will AI do so in healthcare?

107 In clinical trials, AI systems have already shown potential to help clinicians make better diagnoses (Bahl

et al. 2018, Li et al. 2021), help personalise medicine and monitor patient care (Jiang et al. 2017, Ciervo
et al. 2019), and contribute to drug development (Ekins et al. 2019). However, successful application

in practice is limited (Panch et al. 2019: 77) and potential issues that may be responsible for this gap

between research and practice should be revealed by our work.

112 By searching PubMed for the term "artificial intelligence", we found over 2,000 systematic reviews and 113 meta-analyses published in the last 10 years, with a yearly increasing trend. These include several 114 reviews conducted in the area of AI in healthcare that provide an overview of the current state of AI 115 technologies in specific clinical areas, including AI systems for breast cancer diagnosis in screening 116 programmes (Freeman et al. 2021), ovarian cancer (Xu et al. 2022), early detection of skin cancer (Jones 117 et al. 2022), COVID-19 and other pneumonia (Jia et al. 2022), prediction of preterm birth (Akazawa & 118 Hashimoto 2022), or diabetes management (Kamel et al. 2022). Other reviews have focused on 119 comparing clinicians and AI systems in terms of their performance to show their capabilities in a clinical 120 setting (Shen et al. 2019, Nagendran et al. 2020, Liu et al. 2019).

- 121 Although these reviews are crucial to the further development of AI systems, they offer little insight 122 into whether patients actually benefit from their use by medical professionals. Indeed, these studies 123 focus on the analytical performance of these systems, rather than on healthcare-related metrics. In 124 most of the studies mentioned here, the underlying algorithms have been evaluated using a variety of 125 parameters, such as the F1 score for error classification, balanced accuracy, false positive rate, and 126 area under the receiver operating characteristic curve (AUROC). However, measures of a system's 127 accuracy often provide non-replicable results (McDermot et al. 2021: 4), do not necessarily indicate clinical efficiency (Keane & Topol 2018: 1), AUROC does not necessarily indicate clinical applicability 128 129 (Halligan et al. 2015: 935) and in fact, none of these measures reflect beneficial change in patient care 130 (Brocklehurst et al. 2017: 1727, Shah et al. 2019: 1).
- To summarise, as with any other new technology introduced into healthcare, the clinical effectiveness 131 132 and safety of AI compared to the standard of care must be evaluated through properly designed studies to ensure patient safety and maximise benefits while minimising any unintended harm (Park 133 134 et al. 2020: 328). Therefore, a critical analysis of patient-relevant outcomes is needed, especially the 135 benefits and harms of decisions informed by or made by AI systems.
- To this end, this review goes beyond previous studies in several ways. First, we study clinical AI systems 136 137 that enable algorithmic decision making (Al-related ADM) in general and therefore do not limit 138 ourselves to selected clinical problems. In particular, we focus on machine learning systems that infer 139 rules from observations. Although we omit rule-based systems, we apply the term AI throughout our 140 work because it is often incorrectly and redundantly used for ML and deep learning in the literature 141 we study. Second, we focus on studies that report patient-relevant outcomes that, according to 142 German Institute for Quality and Efficiency in Healthcare (IQWiG 2022: 44) describe, how patients feel, 143 how they can perform their functions and activities or if they survive. These may include, for example, 144 mortality, morbidity (with regard to complaints and complications), length of hospital stay, 145 readmission, time to intervention and health-related quality of life. Third, we focus only on studies 146 that compare medical professionals supported by AI-related ADM systems with medical professionals without AI-related ADM systems (standard care). By doing so, this review provides an overview of the 147 148 current literature on clinical AI-related ADM systems, summarises the empirical evidence on their

benefits and harms for patients and highlights research gaps that need to be addressed in futurestudies.

151 If clinical AI systems are found to have a well-balanced benefit-to-harm ratio, their implementation 152 into practice can be considered. However, effectively deploying these systems presents a separate 153 frontier. Specific challenges that need to be addressed include, data privacy and security, usability and 154 lack of algorithm transparency (e.g., in the case of proprietary systems), regulations and policies, the 155 changing nature of healthcare work, the risk of harm from system errors, and at the individual level, 156 physician and patient awareness, education, and trust in these systems (Choudhury et al. 2020: 3, He 157 et al. 2019: 33, Yu et al. 2018: 720).

158 To outline these challenges and framework conditions, particularly in the German healthcare system,

and to consider the empirical data collected in this review, it is necessary to consult experts from

160 various disciplines to use their experiences, knowledge, and perceptions of the benefits and risks of

161 **implementing AI-related ADM systems**. Therefore, we will bring together experts from institutions

responsible for auditing the safety of AI systems, audit bodies that support implementation processes

- 163 under scientific and regulatory conditions in the healthcare sector, and bodies that combine practical
- 164 healthcare work and research with AI systems.
- 165

# 166 **Objectives**

167

The aim of this review is to systematically assess the current evidence on patient-relevant benefits and harms of ADM systems which are developed or used with AI (AI-related ADM) to support medical professionals compared to medical professionals without this support (standard care) (Study 1). Furthermore, we will elicit expert assessments of our findings and the benefits and risks of the implementation of AI-related ADM in healthcare, which they perceive (Study 2).

- 173 Study 1, Systematic review:
- 1741. Are there studies that compare patient-relevant effectiveness of AI-related ADM for medical175professionals compared to medical professionals without AI-related ADM?
- 176 2. Do these studies show adequate methodological quality and are their findings generalisable?
- Can AI-related ADM systems help medical professionals to make better decisions in terms of benefits and harms for patients?
- 179 Study 2, expert interviews:
- How do experts assess the overall benefit-to-harm ratio of identified AI-related ADM systems?
- In which medical area of competences (diagnosis, treatment, prognosis, prevention) would
   patients in Western healthcare systems particularly benefit from AI-related ADM systems?
- What are the consequences (e.g., side effects) of implementing AI-related ADM systems in healthcare?

- What are the main challenges that hinder the implementation of AI-related ADM systems in clinical practice and what improvements could be suggested?
- 188 5. What are the regulatory requirements for implementation of AI-related ADM systems in189 clinical practice?
- 190

# 191 Methods/Design

192

In accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement (Moher et al. 2015), the study protocol for this systematic is registered on the International prospective register of systematic reviews (PROSPERO) database (CRD42023412156). If necessary, post-registration changes to the protocol, will be detailed under the PROSPERO record with an accompanying rationale.

198 To answer the research questions presented, a systematic review in mixed-method design will be 199 conducted, which will be presented into two parts.

# 200 Study 1: Systematic review

201 We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 202 statement (Page et al. 2021) and the Methodological Expectations of Cochrane Intervention Reviews 203 (MECIR) standards (Higgins et al. 2021).

# 204 Searches

We will search systematically using English free text terms in title/abstract, Medical Subject Headings (MeSH) terms and Embase Subject Headings (Emtree) fields for various forms of keywords related to 'artificial intelligence' and relevant subcategories of computer generated and processed decisionmaking algorithms, 'medical professionals' and keywords describing effectiveness parameters and outcomes as well as preferred study types. Based on the block building approach, keywords and terms are combined using the Boolean operators AND and OR and progressively checked for relevant hits.

# 211 Databases to be used for searches

212 MEDLINE and PubMed (via PubMed), EMBASE (via Elsevier), Institute of Electrical and Electronics 213 Engineers (IEEE) Xplore, will be searched for peer-reviewed articles as well as ClinicalTrials.gov and

214 ICTRP (via CENTRAL) for ongoing trials and protocols.

To reduce potential publication bias, additional studies will be identified by contacting authors of included studies, contacting experts in the field, and through reference lists of relevant studies. Grey literature searches will be conducted in Google Scholar. For this purpose, the keywords used in the systematic search will be used in different combinations, as well as their German equivalents. Google Scholar will be searched up to the 10th hit page. The detailed search strategy for each database will be reported under the PROSPERO record once the searches have been conducted.

221

### 222 Search strategy

- 223 We developed our search strategy using the PICOS scheme (Table 1).
- 224 Table 1: PICOS scheme

<b>P</b> articipants	Intervention	<b>C</b> ontrol	<b>O</b> utcome	<b>S</b> tudy Type
Human patients without restriction in age or sex	Medical professionals supported by an AI-related ADM system applied to a clinical problem	Medical professionals applied to a clinical problem, without support by an Al- related ADM system (standard care)	Patient relevant benefits and harms	Interventional and observational studies

225 While doing preliminary searches for basic literature in Medline and PubMed (via PubMed), we noticed 226 that study conductors from different scientific fields (e.g., computer scientists) used different terms 227 for the intervention outcomes we were looking for. In addition, some studies were not indexed 228 appropriately in PubMed, which complicated our initial search strategy. To carry out the search 229 strategy, we have created and tested the blocks consecutively to gather the best results from each 230 block, expanding and narrowing the search strategy. To assess the right direction of the search 231 strategy, we have used fundamental literature, such as Choudhury & Asan 2020, Park et al. 2020 and 232 Nagendran et al. 2020 as test sets, making sure the results of our search had common ground with 233 these studies.

The resulting search string for Medline and PubMed in the individual blocks can be found in table 2and describes the basis for other databases.

- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- 246

#### 247 Table 2: Search string blocks for Medline and PubMed (via PubMed)

Block 1, artificial intelligence:	<pre>(("artificial intelligence"[MeSH Terms] OR "artificial intelligence"[Title/Abstract] OR "artificial-intelligence"[Title/Abstract] OR "machine learning"[Title/Abstract] OR "machine-learning"[Title/Abstract] OR "hierarchical learning"[Title/Abstract] OR "computational intelligence"[Title/Abstract] OR "machine intelligence"[Title/Abstract] OR "computer reasoning"[Title/Abstract] OR "deep learning"[Title/Abstract] OR "supervised learning"[Title/Abstract] OR "unsupervised learning"[Title/Abstract] OR "reinforcement learning"[Title/Abstract] OR "representation learning"[Title/Abstract] OR "natural language processing"[Title/Abstract] OR "large language model*"[Title/Abstract] OR "generative model*"[Title/Abstract] OR "representation learning"[Title/Abstract] OR ("knowledge acquisition"[Title/Abstract] AND "computer"[Title/Abstract]) OR ("knowledge representation"[Title/Abstract] OR "machine vision"[Title/Abstract]) OR "image recognition"[Title/Abstract] OR "machine vision"[Title/Abstract]])</pre>
Block 2, medical professionals:	AND ("expert"[Title/Abstract] OR "experts"[Title/Abstract] OR "medical professional"[Title/Abstract] OR "medical professionals"[Title/Abstract] OR "medical doctor*"[Title/Abstract] OR "physician*"[Title/Abstract] OR "clinician*"[Title/Abstract] OR "general practitioner*"[Title/Abstract] OR "health care professional"[Title/Abstract] OR "health care professionals"[Title/Abstract] OR "healthcare professional"[Title/Abstract] OR "health care professionals"[Title/Abstract] OR "nurse"[Title/Abstract] OR "nurses"[Title/Abstract] OR "healthcare professional"[Title/Abstract] OR "healthcare professionals"[Title/Abstract] OR "nurse"[Title/Abstract] OR "nurses"[Title/Abstract]] OR ("therapist"[Title/Abstract] OR "therapists"[Title/Abstract]] OR ("health"[Title/Abstract] AND "alert system"[Title/Abstract]] OR ("medical"[Title/Abstract] AND "alert system"[Title/Abstract]] OR ("hospital"[Title/Abstract] AND "alert system"[Title/Abstract]] OR ("hospital"[Title/Abstract] AND "alert system"[Title/Abstract]] OR ("hospital"[Title/Abstract] AND "alert system"[Title/Abstract]] OR ("health"[Title/Abstract] AND "alert system"[Title/Abstract]] OR ("health"[Title/Abstract] AND "alert system"[Title/Abstract]] OR ("health"[Title/Abstract] AND "decision support"[Title/Abstract]] OR ("health"[Title/Abstract] AND "warning system"[Title/Abstract]] OR ("health"[Title/Abstract] AND "warning system"[Title/Abstract]] OR ("health"[Title/Abstract] AND "warning system"[Title/Abstract]] OR ("health"[Title/Abstract] AND "warning system"[Title/Abstract]] OR ("health"[Title/Abstr
Block 3, outcomes:	AND ("effectiveness"[Title/Abstract] OR "effectivity"[Title/Abstract] OR "benefit"[Title/Abstract] OR "benefits"[Title/Abstract] OR "harm"[Title/Abstract] OR "harms"[Title/Abstract] OR "adverse event*"[Title/Abstract] OR "mortality"[Title/Abstract] OR "morbidity"[Title/Abstract] OR "length of hospital stay"[Title/Abstract] OR "readmission"[Title/Abstract] OR "time to intervention"[Title/Abstract] OR "health-related quality of life"[Title/Abstract] OR "endpoint*"[Title/Abstract] OR "outcome*"[Title/Abstract])
Block 4, study types:	AND ("randomised" OR "randomized" OR "RCT" OR "clinical trial*" OR "cohort" OR "observational study" OR "observational design*" OR "case-control" OR "experiment*" OR "retrospective study" OR "retrospective design*" OR "prospective study" OR "prospective design*" OR "non-inferiority" OR "phase* study" OR "intervention study" OR "diagnostic study" OR "pre-post study" OR "pre post study" OR "pre-post design" OR "pre post design")
Filter:	AND (humans[filter]) AND (y_10[filter])

#### 249 Types of studies to be included

- 250 For the systematic search peer reviewed interventional and observational studies published in German
- or English, 10 years retrospectively from the date of the search will be considered. For the search of
- grey literature, scientific reports published in German or English 10 years retrospectively from the date
- 253 of the search will be considered. To extract potentially relevant studies from (systematic) reviews and
- 254 meta-analyses, secondary studies will be gathered and screened. However, secondary studies will not
- be included in the synthesis.
- In contrast to studies of effectiveness and safety, pure efficacy studies (e.g., focusing on algorithms
   accuracy) will be excluded as these outcomes are not directly relevant for patients. Patient-relevant
   outcomes will be defined according to the IQWiG method paper (2022). In addition, studies that used
- Al systems beyond our scopes, such as robotics (systems that support the implementation of decisions)
- 260 will be excluded. Editorials, commentaries, letters, and other informal publication types will be
- 261 excluded as well.
- We will provide a list of all references screened in full text including exclusion reasons in the appendix of the final study.

### 264 Participants

- 265 Our study is focusing on human patients without restriction of age or sex. Therefore, the input data
- 266 for the algorithms must include real human data gathered either during routine care and saved for use
- 267 in research or generated specifically for the individual study.

## 268 Intervention

- 269 Out study is focusing on medical professionals utilizing an AI-related ADM system to address a clinical270 problem.
- In our working definition, a medical professional is a qualified individual who has the authority to perform necessary medical procedures within their professional scope of practice. Their goal is to improve, maintain, or restore the health of individuals by examining, diagnosing, prognosticating, and/or treating clinical problems. This may include medical doctors, registered nurses, and other medical professionals. Clinical problems can encompass illnesses, injuries, and physical or mental disorders, among other conditions.
- 277 In our working definition, an AI-related ADM system is a clinical decision support system that either
- apply AI (e.g., relying on ML models) or that has been developed with the help of AI. Clinical decision
- 279 support models without any involvement of AI will be excluded.

## 280 Control

- 281 Medical professionals, as described in the working definition, are addressing a clinical problem without
- the support of an AI-related ADM system (standard care).

#### 283 Outcomes

284 Patient-relevant benefits and harms, according to the IQWiG method paper (2022), are gathered.

285 These may include, for example, mortality, morbidity (with regard to complaints and complications),

length of hospital stay, readmission, time to intervention and health-related quality of life.

#### 287 Study types

288 We will collect both interventional and observational studies, which may encompass randomised 289 controlled trials, cohort studies, case-control studies, randomised surveys, retrospective and 290 prospective studies, phase studies, as well as non-inferiority or diagnostic studies.

#### 291 Data extraction

292 Records arising from the literature search will be stored in the citation manager Citavi 6 (c) Swiss 293 Academic Software. After removing duplicates, two reviewers will independently review all titles and 294 abstracts via the browser application Rayyan (Ouzzani et al. 2016). Studies potentially meeting the 295 inclusion criteria will then be screened in full text independently by two reviewers. Disagreements over 296 eligibility of studies will be discussed and, if necessary, resolved by a third reviewer. Authors of the 297 included studies will be contacted if clarification of their data or study methods is required. The 298 PRISMA 2020 flow diagram (Page et al. 2021) will be used to keep the study selection process 299 transparent.

300 Using a standardised data collection form, two reviewers will extract data independently from the 301 included studies and will compare them for discrepancies. Missing data will be requested from study 302 authors. Extracted data will include the following (Table 3).

- 303
- 304
- 305
- 306
- 307
- 308
- 309
- 310
- ....
- 311
- 312

### 313 Table 3: Study data to be extracted

Table/ Item	Example	
Study characteristics		
Reference, registration	Meier, 2022	
Country of conduction	Germany	
Setting	Hospital	
Study design	RCT	
Observation duration	January 2017 until September 2018	
Medical specialty	Intensive care unit (ICU)	
Prediction/ classification goal of AI-related ADM	Sepsis	
Patient-relevant outcome	Mortality, length of hospital stay	
Intervention procedure/ instrument	ICU bedside monitors with recommender	
comparison procedure/ instrument	ICU bedside monitors without recommender	
Study funding	No funding	
Characteristics of the evaluation populat	ion	
Patient population		
Inclusion criteria	Participants age over 18 under 64	
Exclusion criteria	Pre-existing septic shock	
Mean age (SD)	49.8 (1.55)	
Population total (share of sex in %)	N=75 (n=30 females)	
Medical professional population		
Inclusion criteria	ICU Physician, trained in used AI-related ADM system	
Exclusion criteria	Physician at ICU for less than 2 years	
Mean age (SD)	45.0 (3.5)	
Population total (share of sex in %)	N=6 (n=3 females)	
Characteristics of used algorithm		
Algorithm name	ResNet-18	
Algorithm architecture	Convolutional neural network (CNN)	
Data source	In house digital medical records, monitoring data	
Development	Laboratory and health metrics (HR, RR, SpO2, etc.) of	
	n=677 cases (n=220 females)	
Validation	Internal: random split sample, external: no	
Risk of bias assessment (RoB 2/ ROBINS-	I)	
Reporting assessment (CONSORT-AI)		
Study Results		
Supported decision	Initiation of life-saving measures, hospital discharge	
Patient benefit (effect size)	Reduction length of hospital stay: 2.3 days	
, , , , , , , , , , , , , , , , , , ,	Mortality rate reduction: 12/100 patients	
	Reduction length of stay ICU: 0 days	
Patient harm (effect size)	Not reported	
Other effects	Not reported	
Assessment for clinical use		
Implementation status	Not implemented	
Author's restrictions on clinical use	System requires more training and testing	
Author's recommendation on clinical	Not mentioned	
use		

#### 315 Risk of bias and quality assessment

316 Risk of bias will be assessed by using the revised Cochrane risk-of-bias tool for randomized trials (RoB 317 2) (Sterne et al. 2019) and the risk-of-bias in non-randomized studies for interventions (ROBINS-I) tool 318 (Sterne et al. 2017). Disagreements between the authors over the risk of bias in the included studies 319 will be resolved by discussion, or with involvement of a third author if necessary. Transparent reporting 320 of the included studies will be assessed trough the Consolidated Standards of Reporting Trials 321 interventions involving Artificial Intelligence (CONSORT-AI) extension by Liu et al. (2020). The 322 CONSORT-AI extension includes 14 new items that were considered sufficiently important for AI 323 interventions to be routinely reported in addition to the core CONSORT items by Schulz et al. (2010). 324 CONSORT-AI aims to improve the transparency and completeness in reporting clinical trials for AI 325 interventions. It will assist to understand, interpret, and critically appraise the quality of clinical trial 326 design and risk of bias in the reported outcomes.

#### 327 Data synthesis

328 Given the expected likelihood of heterogeneity between studies in the different medical specialties in 329 terms of outcome measures, study designs and interventions, we do not know if performing a meta-330 analysis will be possible. However, a systematic narrative synthesis will be provided of the results with 331 an overview of the relevant effects for the outcomes, with information presented in the text and tables 332 to summarise and explain the characteristics and findings of the included studies. The measures will be presented in absolute risks and risk differences. Studies of unclear or high risk of bias will not be 333 334 excluded, as the authors assume that most potentially relevant studies will be of low methodological 335 quality. This is also reported in recent reviews that examine the methodological quality of machine 336 learning systems in the clinical setting (e.g., Nagendran et al. 2020). Nevertheless, the influence of the 337 potential biases on the results will be discussed.

In addition to the synthesis trough Study 1, the results of this review will be discussed with experts(Study 2) and presented in the text.

#### 340 Study 2: Expert interviews

In order to meet the study objectives, and considering the findings of Study 1, we elicit experts' experiences, knowledge, and their perceived benefits and risks of implementing AI-related ADM systems. By doing so, we hope to gain a practice-related understanding of the findings of Study 1 and identify barriers and needs regarding future research questions.

Based on the research questions and the findings of Study 1, the study and interview guide will be developed a priori. The study design and the interview guide will be submitted to the ethics committee of the University of Potsdam and pre-registered within the PROSPERO protocol for the systematic review. If necessary, post-registration changes to the protocol will be detailed and justified in the PROSPERO protocol. To ensure transparency of the qualitative research part of our review, we will follow the Standards for Reporting Qualitative Research (SRQR) (O'Brien et al. 2014).

### 351 Study design

We will conduct semi-structured interviews. To analyse the interviews, we will use qualitative content analysis according to Mayring (2020). This systematic and rule-based approach will ensure that the

analysis is understandable, comprehensible, and verifiable by others.

### 355 Data collection

356 As our interview study aims to understand the practical implications of the findings of Study 1, we will 357 use a purposive sampling strategy to select at least 3 interviewees according to their expertise through 358 their function, profession, practice, and research in relation to the research questions (Mey & Mruck 359 2020: 322, Schreier 2020: 24). Therefore, we will combine experts of the following types: Auditing 360 bodies responsible for auditing AI systems for safety (e.g., TÜV NORD IT Secure Communications GmbH 361 & Co. KG), auditing bodies that support implementation procedures under scientific and regulatory 362 conditions in the healthcare sector (e.g., VDI/VDE Innovation + Technik GmbH), and institutions that 363 combine practical healthcare-related work and research with AI systems (e.g., Berlin Institute of Health 364 at Charité Berlin). The experts will be recruited on the basis of publications, via professional networks, and by sending inquiries to the relevant organisations and institutions. Once relevant experts will have 365 366 been identified, they will be contacted via e-mail or phone, informing about the specific research 367 questions, and showing some exemplary findings from Study 1, to ask for participation and to set the scope of the interview. There is no reimbursement planned for the experts who participate in the 368 369 interview.

370 Written informed consent will be obtained prior to each interview and participants will be fully 371 informed in writing and verbally about the purpose, risks, and scope of the study.

Approximately one week prior to the interview, participants will be presented with the key findings of Study 1 and the interview guide, which they will be asked about in the interview. In addition to the questions on research interest, descriptive data will be collected on field of activity, specific expertise, organisation, length of involvement in the topic, as well as age and gender of the respective interviewee. Interviews should not exceed 45 minutes. All interviews will be audio recorded and automatically transcribed verbatim using Adobe Premiere Pro 2023 (version 23.1.0). The automated transcripts will be corrected manually by the interviewer.

Throughout the data collection process, the interviewer will keep a research diary to record initial impressions immediately after each interview and to encourage reflexivity about how their role in the researcher-participant relationship might influence the data collection process (Mayring 2020: 12).

#### 382 Data analysis and extraction

The transcripts and notes from the research diary will be transferred to the relevant memos of each transcript in MAXQDA Plus 2022 (version 22.2.0). All data analysis will be carried out by two independent researchers to ensure rigour and trustworthiness. In the event of disagreement between

the two researchers on coding, we will revisit the data to develop a shared understanding of the consistent interpretations. The interviews will be analysed using qualitative content analysis according to Mayring (2020). The main categories will initially be developed deductively from the interview guide, which will be developed from the findings of Study 1. Additional major categories will be developed inductively from the data. The final code system, including illustrative interview quotes, will be part of the scientific publication. For this purpose, extracts from the transcript will be translated into English

392 after coding, if necessary.

#### 393 Data management, data storage and data privacy

394 After being contacted by the interviewer via phone or e-mail, the experts will receive all relevant study 395 documents via mail or e-mail. Verbal consent to receive the study documents will be obtained by 396 phone or e-mail, and written consent will be obtained in the consent form before the interview takes 397 place. All participants will be assured of confidentiality, anonymity of data, and the right to withdraw 398 from the study or skip questions without negative consequences. Individual contact details will be 399 stored on the interviewer's password-protected computer until the time of the interview. Contact 400 details will be deleted immediately after the interview. The audio recording is used only for quality 401 assurance and will be deleted immediately after it is transcribed and compared. Transcripts will be 402 pseudonymised by changing personal characteristics (such as names and addresses) and personal data, 403 i.e., data that make indirect identification possible (e.g., places or institutions) to pseudonyms.

404

# 405 **Discussion**

406

407 It is to be expected that there is a significant lack of suitable studies comparing healthcare professionals 408 with and without AI-related ADM systems regarding patient-relevant outcomes. It is assumed that this 409 is due to, first, the lack of approval regulations for AI systems, second, the prioritisation of technical 410 and clinical parameters over patient-relevant outcomes in the development of study designs, and, 411 third, the prioritisation of AI for supporting clinical processes (e.g., administration). In addition, it is to 412 be expected that a large proportion of the studies to be identified are of rather poor methodological 413 quality and provide results that are rather difficult to generalise. Although reporting guidelines such as the Consolidated Standards of Reporting Trials (CONSORT) Statement (Schulz et al. 2010) are well-414 415 known and widely used in medical and public health research, they do not necessarily correspond to 416 the novel protocol and study designs that are relevant for the assessment of the research questions 417 relevant here. The extension of the Reporting Guidelines for Clinical Study Reports of Interventions 418 Using Artificial Intelligence (CONSORT-AI) (Liu et al. 2020) may fill the gap but this guideline is relatively 419 new and not necessarily always applied.

Engaging in discussions with experts from AI safety audit organizations, healthcare implementation audit bodies, and institutions bridging healthcare practice and AI research, we will gain valuable insights into the implications of study 1's findings (e.g., explanations for limited patient-relevant

- 423 studies). Additionally, these discussions will illuminate the challenges and opportunities associated
- with the integration of AI-related ADM systems in healthcare practice and enlighten their benefits andharms for patients.

- -

- -3-

# 451 List of abbreviations

- 452
- Algorithmic Decision Making. 453 ADM Artificial Intelligence. 454 AI 455 AUROC Area Under the Receiver Operating Characteristic Curve. 456 CENTRAL Cochrane Central Register of Controlled Trials. 457 Convolutional Neural Network. CNN 458 CONSORT Consolidated Standards of Reporting Trials. Consolidated Standards of Reporting Trials for Artificial Intelligence. 459 **CONSORT-AI** 460 CRD Centre for Reviews and Dissemination. 461 EMTREE Embase subject headings. 462 HR Heart Rate. 463 ICU Intensive Care Unit. 464 IEEE Institute of Electrical and Electronics Engineers 465 IQWiG German Institute for Quality and Efficiency in Healthcare. 466 MECIR Methodological Expectations of Cochrane Intervention Reviews. MeSH 467 Medical Subject Headings. 468 ML Machine Learning. non Randomized Controlled Trial. 469 nRCT Participants, Intervention, Control, Outcome. 470 PICO 471 PRISMA Preferred Reporting Items for Systematic Review and Meta-Analysis. 472 PRISMA-P Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. 473 PROSPERO International Prospective Register of Systematic Reviews. Randomized Controlled Trial. 474 RCT 475 ResNet-18 A convolutional neural network that is 18 layers deep. Revised Cochrane Risk-of-Bias Tool for randomized trials. 476 RoB 2 477 **ROBINS-I** Risk-of-Bias in non-randomized studies for interventions.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.27.24304965; this version posted March 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a 🖒	C-BY-NC-ND 4.0 International license
--------------------------------	--------------------------------------

478	RR	Respiratory Rate.
479	SD	Standard Deviation.
480	SpO2	Oxygen Saturation.
481	SRQR	Standards for Reporting Qualitative Research.
482		
483		
484		
485		
486		
487		
488		
489		
490		
491		
492		
493		
494		
495		
496		
497		
498		
499		
500		
501		
502		
503		
504		
505		
506		
507		
508		

# 509 **Declarations**

510

## 511 Ethics approval and consent to participate

- 512 Ethical approval for this study was obtained from the Ethics Committee of the University of Potsdam
- 513 (103/2023).

514

- 515 **Consent for publication**
- 516 Not applicable.
- 517
- 518 Availability of data and materials
- 519 Not applicable.
- 520

## 521 **Competing interests**

- 522 The authors declare that they have no competing interests.
- 523
- 524 Funding
- 525 This research does not receive any funding.

526

- 527 Acknowledgements
- 528 Not applicable

529

- 530
- 531
- 532
- 533
- 534
- - -
- 535
- 536

#### References 537

- 538
- 539 Akazawa M, Hashimoto K. Prediction of preterm birth using artificial intelligence: a systematic 540 review. J Obstet Gynaecol. 2022 Aug;42(6):1662-1668. doi: 541 10.1080/01443615.2022.2056828. 542 Araujo T, Helberger N, Kruikemeier S, de Vreese CH. In AI we trust? Perceptions about automated decision-making by artificial intelligence. AI & Soc 35, 611-623 (2020). doi: 10.1007/s00146-543 544 019-00931-w.
- 545 Bahl M, Barzilay R, Yedidia AB, Locascio NJ, Yu L, Lehman CD. High-Risk Breast Lesions: A Machine Learning Model to Predict Pathologic Upgrade and Reduce Unnecessary Surgical Excision. 546 547 Radiology. 2018 Mar;286(3):810-818. doi: 10.1148/radiol.2017170549.
- 548 Brocklehurst P, Field D, Greene K, Juszczak E, Keith R, Kenyon S, et al. Computerised interpretation of 549 fetal heart rate during labour (INFANT): a randomised controlled trial. Lancet. 550 2017;389:1719-29. doi: 10. 1016/s0140-6736(17)30568-8.
- 551 Choudhury A, Asan O. Role of Artificial Intelligence in Patient Safety Outcomes: Systematic Literature Review. JMIR Med Inform. 2020 Jul 24;8(7):e18599. doi: 10.2196/18599. 552
- 553 Ciervo J, Shen SC, Stallcup K, Thomas A, Farnum MA, Lobanov VS, Agrafiotis DK. A new risk and issue 554 management system to improve productivity, quality, and compliance in clinical trials. JAMIA 555 Open. 2019 Mar 19;2(2):216-221. doi: 10.1093/jamiaopen/ooz006.
- 556 Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, Hickey AJ, Clark AM. Exploiting machine 557 learning for end-to-end drug discovery and development. Nat Mater. 2019 May;18(5):435-558 441. doi: 10.1038/s41563-019-0338-z.
- 559 EQUATOR. Enhancing the QUAlity and Transparency Of health Research. 2021. http://www.equator-560 network.org. Accessed 21 November 2023.
- 561 Freeman K, Geppert J, Stinton C, Todkill D, Johnson S, Clarke A, Taylor-Phillips S. Use of artificial 562 intelligence for image analysis in breast cancer screening programmes: systematic review of 563 test accuracy. BMJ. 2021 Sep 1;374:n1872. doi: 10.1136/bmj.n1872.
- 564 Graili P, Ieraci L, Hosseinkhah N, Argent-Katwala M. Artificial intelligence in outcomes research: a 565 systematic scoping review. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):601-623. doi: 10.1080/14737167.2021.1886083. 566
- 567 Halligan S, Altman DG, Mallett S. Disadvantages of using the area under the receiver operating characteristic curve to assess imaging tests: a discussion and proposal for an alternative 568 569 approach. Eur Radiol. 2015 Apr;25(4):932-9. doi: 10.1007/s00330-014-3487-0.
- 570 He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. Nat Med. 2019 Jan;25(1):30-36. doi: 10.1038/s41591-018-0307-0. 571
- 572 Higgins J, Lasserson T, Chandler J, Tovey D, Thomas J, Flemyng E, Churchill R. Methodological 573 Expectations of Cochrane Intervention Reviews (MECIR). Standards for the conduct and 574 reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, 575 conduct and reporting of updates. 2021.
- 576 https://community.cochrane.org/sites/default/files/uploads/MECIR-February-2021.pdf. 577 Accessed 12 November 2023.
- 578 Hughes A. ChatGPT: Everything you need to know about OpenAl's GPT-3 tool. BBC Science Focus Magazine. https://www.sciencefocus.com/future-technology/gpt-3/. 2023. Accessed 12 579 580 November 2023.

#### 581 Institute for Quality and Efficiency in Healthcare (IQWiG). Allgemeine Methoden. Version 6.1, from 582 24<sup>th</sup> of January 2022. https://www.iqwig.de/methoden/allgemeine-methoden-v6-1.pdf. 583 2022. Accessed 12 November 2023.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.27.24304965; this version posted March 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 584 Jia LL, Zhao JX, Pan NN, Shi LY, Zhao LP, Tian JH, Huang G. Artificial intelligence model on chest 585 imaging to diagnose COVID-19 and other pneumonias: A systematic review and meta-586 analysis. Eur J Radiol Open. 2022;9:100438. doi: 10.1016/j.ejro.2022.100438. Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, Wang Y, Dong Q, Shen H, Wang Y. Artificial intelligence in 587 588 healthcare: past, present and future. Stroke Vasc Neurol. 2017 Jun 21;2(4):230-243. doi: 589 10.1136/svn-2017-000101. 590 Jones OT, Matin RN, van der Schaar M, Prathivadi Bhayankaram K, Ranmuthu CKI, Islam MS, Behiyat 591 D, Boscott R, Calanzani N, Emery J, Williams HC, Walter FM. Artificial intelligence and 592 machine learning algorithms for early detection of skin cancer in community and primary 593 care settings: a systematic review. Lancet Digit Health. 2022 Jun;4(6):e466-e476. doi: 594 10.1016/S2589-7500(22)00023-1. 595 Kamel Rahimi A, Canfell OJ, Chan W, Sly B, Pole JD, Sullivan C, Shrapnel S. Machine learning models 596 for diabetes management in acute care using electronic medical records: A systematic 597 review. Int J Med Inform. 2022 Apr 2;162:104758. doi: 10.1016/j.ijmedinf.2022.104758. 598 Keane PA, Topol EJ. With an eye to AI and autonomous diagnosis. NPJ Digit Med. 2018 Aug 28;1:40. 599 doi: 10.1038/s41746-018-0048-y. Kung TH, Cheatham M, Medenilla A, Sillos C, De Leon L, Elepaño C, Madriaga M, Aggabao R, Diaz-600 601 Candido G, Maningo J, Tseng V. Performance of ChatGPT on USMLE: Potential for AI-assisted 602 medical education using large language models. PLOS Digit Health. 2023 Feb 603 9;2(2):e0000198. doi: 10.1371/journal.pdig.0000198. 604 Li Q, Zhao K, Bustamante CD, Ma X, Wong WH. Xrare: a machine learning method jointly modeling 605 phenotypes and genetic evidence for rare disease diagnosis. Genet Med. 2019 606 Sep;21(9):2126-2134. doi: 10.1038/s41436-019-0439-8. 607 Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK; SPIRIT-AI and CONSORT-AI Working Group. 608 Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: 609 the CONSORT-AI extension. Nat Med. 2020 Sep;26(9):1364-1374. doi: 10.1038/s41591-020-610 1034-x. Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, Mahendiran T, Moraes G, Shamdas M, Kern C, 611 Ledsam JR, Schmid MK, Balaskas K, Topol EJ, Bachmann LM, Keane PA, Denniston AK. A 612 613 comparison of deep learning performance against health-care professionals in detecting 614 diseases from medical imaging: a systematic review and meta-analysis. Lancet Digit Health. 615 2019 Oct;1(6):e271-e297. doi: 10.1016/S2589-7500(19)30123-2. Mayring P. Qualitative Inhaltsanalyse. In: Mey G, Mruck K, editors. Handbuch Qualitative Forschung 616 in der Psychologie. 2<sup>nd</sup> ed. Wiesbaden: Springer Fachmedien; 2020. p. 495-511. 617 McCarthy J, Minsky M, Rochester N, Shannon C. A proposal for the Dartmouth summer research 618 619 project on artificial intelligence, August 31, 1955. Al Magazine 2006;27(4):12. doi: 10.1609/aimag.v27i4.1904. 620 621 Mey G, Mruck K. Qualitative Interviews. In: Mey G, Mruck K, editors. Handbuch Qualitative Forschung in der Psychologie. 2<sup>nd</sup> ed. Wiesbaden: Springer Fachmedien; 2020. p. 315-336. 622 623 Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred 624 Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 625 statement. Syst Rev. 2015;4(1):1. doi: 10.1609/aimag.v27i4.1904. Nagendran M, Chen Y, Lovejoy CA, Gordon AC, Komorowski M, Harvey H, Topol EJ, Ioannidis JPA, 626 627 Collins GS, Maruthappu M. Artificial intelligence versus clinicians: systematic review of 628 design, reporting standards, and claims of deep learning studies. BMJ. 2020 Mar 25;368:m689. doi: 10.1136/bmj.m689. 629 630 O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting gualitative research: a 631 synthesis of recommendations. Acad Med. 2014 Sep;89(9):1245-51. doi: 632 10.1097/ACM.00000000000388.

OpenAI. Introducing ChatGPT. 2023. https://openai.com/blog/chatgpt. Accessed 12 November 2023. 633 634 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid, A. Rayyan - a web and mobile app for systematic 635 reviews. Syst Rev 5, 210 (2016). doi: 10.1186/s13643-016-0384-4. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl 636 637 EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, 638 Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, 639 Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting 640 systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. 641 Panch T, Mattie H, Celi LA. The "inconvenient truth" about Al in healthcare. NPJ Digit Med. 2019 Aug 16;2:77. doi: 10.1038/s41746-019-0155-4. 642 Park Y, Jackson GP, Foreman MA, Gruen D, Hu J, Das AK. Evaluating artificial intelligence in medicine: 643 644 phases of clinical research. JAMIA Open. 2020 Sep 8;3(3):326-331. doi: 645 10.1093/jamiaopen/ooaa033. 646 Schreier M. Fallauswahl. In: Mey G, Mruck K, editors. Handbuch Qualitative Forschung in der 647 Psychologie. 2<sup>nd</sup> ed. Wiesbaden: Springer Fachmedien; 2020. p. 19-39. 648 Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for 649 reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332. 650 651 Shah NH, Milstein A, Bagley PhD SC. Making Machine Learning Models Clinically Useful. JAMA. 2019 652 Oct 8;322(14):1351-1352. doi: 10.1001/jama.2019.10306. 653 Shen J, Zhang CJP, Jiang B, Chen J, Song J, Liu Z, He Z, Wong SY, Fang PH, Ming WK. Artificial 654 Intelligence Versus Clinicians in Disease Diagnosis: Systematic Review. JMIR Med Inform. 655 2019 Aug 16;7(3):e10010. doi: 10.2196/10010. 656 Silver D, Hubert T, Schrittwieser J, Antonoglou I, Lai M, Guez A, Lanctot M, Sifre L, Kumaran D, 657 Graepel T, Lillicrap T, Simonyan K, Hassabis D. A general reinforcement learning algorithm 658 that masters chess, shogi, and Go through self-play. Science. 2018 Dec 7;362(6419):1140-659 1144. doi: 10.1126/science.aar6404. 660 Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, 661 Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, 662 663 Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, 664 Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919. 665 666 Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, 667 668 Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling 669 K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in 670 randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898. 671 Xu HL, Gong TT, Liu FH, Chen HY, Xiao Q, Hou Y, Huang Y, Sun HZ, Shi Y, Gao S, Lou Y, Chang Q, Zhao YH, Gao QL, Wu QJ. Artificial intelligence performance in image-based ovarian cancer 672 673 identification: A systematic review and meta-analysis. EClinicalMedicine. 2022 Sep 674 17;53:101662. doi: 10.1016/j.eclinm.2022.101662. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018 Oct;2(10):719-675 731. doi: 10.1038/s41551-018-0305-z. 676